- Public Comps
- Jasper Therapeutics
Jasper Therapeutics Valuation Multiples
Discover Jasper Therapeutics' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Dare Bioscience, Tvardi Therapeutics, Sangamo Therapeutics, Nanogroup and more.
Jasper Therapeutics Overview
About Jasper Therapeutics
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Founded
2019
HQ

Employees
64
Website
Financials (LTM)
EV
$16M
Valuation Multiples
Start free trialJasper Therapeutics Financials
Jasper Therapeutics reported last 12-month revenue of - and negative EBITDA of ($64M).
In the same LTM period, Jasper Therapeutics generated - in gross profit, ($64M) in EBITDA losses, and had net loss of ($54M).
Revenue (LTM)
Jasper Therapeutics P&L
In the most recent fiscal year, Jasper Therapeutics reported revenue of - and EBITDA of ($83M).
Jasper Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Jasper Therapeutics Stock Performance
Jasper Therapeutics has current market cap of $29M, and enterprise value of $16M.
Market Cap Evolution
Jasper Therapeutics' stock price is $0.88.
Jasper Therapeutics share price increased by 110.2% in the last 30 days, and decreased by 69.5% in the last year.
Jasper Therapeutics has an EPS (earnings per share) of $-2.28.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $16M | $29M | 0.0% | 110.2% | -4.7% | -69.5% | $-2.28 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJasper Therapeutics Valuation Multiples
Jasper Therapeutics trades at (0.3x) EV/EBITDA.
EV / Revenue (LTM)
Jasper Therapeutics Financial Valuation Multiples
As of July 19, 2026, Jasper Therapeutics has market cap of $29M and EV of $16M.
Jasper Therapeutics has a P/E ratio of (0.5x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Jasper Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Jasper Therapeutics Margins & Growth Rates
Jasper Therapeutics decreased EBITDA by 41% in the last fiscal year.
Jasper Therapeutics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Jasper Therapeutics Operational KPIs
Jasper Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Jasper Therapeutics Competitors
Jasper Therapeutics competitors include Dare Bioscience, Tvardi Therapeutics, Sangamo Therapeutics, Nanogroup, Poltreg, MindMaze Therapeutics, BioXcel Therapeutics, Spirit Scientific Co, Oncocross and Lipum.
Most Jasper Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 12.1x | 7.7x | (1.0x) | - | |||
| - | - | (0.2x) | (0.2x) | |||
| 0.6x | 0.6x | (0.2x) | - | |||
| - | - | (10.0x) | - | |||
| - | 16.0x | (8.3x) | (12.6x) | |||
| 27.3x | 5.0x | (2.2x) | (2.4x) | |||
| 172.1x | 90.9x | (2.2x) | (2.4x) | |||
| 2.8x | - | 13.4x | - | |||
This data is available for Pro users. Sign up to see all Jasper Therapeutics competitors and their valuation data. Start Free Trial | ||||||
Jasper Therapeutics VC Funding History
Before going public, Jasper Therapeutics raised $49M in total equity funding, across 2 rounds.
Jasper Therapeutics Funding Rounds
Acquisitions by Jasper Therapeutics
Jasper Therapeutics has acquired 1 company to date.
Last acquisition by Jasper Therapeutics was on July 15th 2026. Jasper Therapeutics acquired Kira Pharmaceuticals for $132M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Jasper Therapeutics
| Description | - |
| HQ Country | |
| HQ City | Hong Kong |
| Deal Date | 15 Jul 2026 |
| Valuation | $132M |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Jasper Therapeutics acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Jasper Therapeutics
| When was Jasper Therapeutics founded? | Jasper Therapeutics was founded in 2019. |
| Where is Jasper Therapeutics headquartered? | Jasper Therapeutics is headquartered in United States. |
| How many employees does Jasper Therapeutics have? | As of today, Jasper Therapeutics has over 64 employees. |
| Who is the CEO of Jasper Therapeutics? | Jasper Therapeutics' CEO is Jeet Mahal. |
| Is Jasper Therapeutics publicly listed? | Yes, Jasper Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Jasper Therapeutics? | Jasper Therapeutics trades under JSPR ticker. |
| When did Jasper Therapeutics go public? | Jasper Therapeutics went public in 2021. |
| Who are competitors of Jasper Therapeutics? | Jasper Therapeutics main competitors include Dare Bioscience, Tvardi Therapeutics, Sangamo Therapeutics, Nanogroup, Poltreg, MindMaze Therapeutics, BioXcel Therapeutics, Spirit Scientific Co, Oncocross, Lipum. |
| What is the current market cap of Jasper Therapeutics? | Jasper Therapeutics' current market cap is $29M. |
| Is Jasper Therapeutics profitable? | No, Jasper Therapeutics is not profitable. |
| What is the current EBITDA of Jasper Therapeutics? | Jasper Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Jasper Therapeutics? | Current EBITDA multiple of Jasper Therapeutics is (0.3x). |
| How many companies Jasper Therapeutics has acquired to date? | As of July 2026, Jasper Therapeutics has acquired 1 company. |
| What was the largest acquisition by Jasper Therapeutics? | $132M acquisition of Kira Pharmaceuticals on 15th July 2026 was the largest M&A Jasper Therapeutics has done to date. |
| What companies Jasper Therapeutics acquired? | Jasper Therapeutics acquired Kira Pharmaceuticals. |
| In how many companies Jasper Therapeutics has invested to date? | Jasper Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Jasper Therapeutics
Lists including Jasper Therapeutics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.





